Biggest News Aggregation in the World
📰 Advanced Solid Tumors News

Page 5 - Advanced Solid Tumors News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.

MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annu

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M...
United States Eamonn Nolan Thomas Biegi Julia Neugebauer Tim Demuth Xencor Inc

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 ... | May 11, 2023
Myriam Chalabi Michaela Curran Patricia Lorusso Shawn Iadonato John Mullaly Evany Yu

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.
United States Marwang Fakih Judy Bernard Briskin J Randolph Hecht David Geffen School Of Medicine Gastrointestinal Gi Oncology Program

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
United States Matthewh Taylor Providence Cancer Institute Melanoma Program Providence Cancer Institute Thyroid Program Developmental Cancer Therapeutics Laboratory Research Institute

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science